Pegylated liposomal‑paclitaxel induces ovarian cancer cell apoptosis via TNF‑induced ERK/AKT signaling pathway

Qi,Zhiying; Yin,Lirong; Xu,Yanying; Wang,Fang

doi:10.3892/mmr.2018.8811

Pegylated liposomal‑paclitaxel induces ovarian cancer cell apoptosis via TNF‑induced ERK/AKT signaling pathway

Authors:
- Zhiying Qi
- Lirong Yin
- Yanying Xu
- Fang Wang
View Affiliations

Affiliations: Department of Gynaecology and Obstetrics, The Second Hospital of Tianjin Medical University, Tianjin 300211, P.R. China
Published online on: March 28, 2018 https://doi.org/10.3892/mmr.2018.8811
Pages: 7497-7504
Copyright: © Qi et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Ovarian cancer is one of the most common gynecological types of cancer and is characterized by a relatively high incidence and high mortality rate. Evidence has demonstrated that paclitaxel (PTX) is an effective therapeutic treatment for human ovarian cancer. In the present study, the inhibitory effects of pegylated liposomal (PL)‑PTX on the growth of ovarian cancer cells were investigated in vitro; a CAOV‑3‑bearing mouse model was established to investigate the in vivo effects of PL‑PTX on ovarian tumor growth. In the present study, the underlying mechanism of tumor necrosis factor (TNF)‑induced inhibition of extracellular signal‑regulated kinase (ERK)/protein kinase B (AKT) signaling pathway mediated by PL‑PTX was analyzed within ovarian cancer cells. The results of the present study revealed that PL‑PTX significantly inhibited the growth and aggressiveness of ovarian cancer cells in vitro and in vivo and apoptotic ability increased upon administration of PL‑PTX. The expression levels of caspase‑3/9 were significantly upregulated within PL‑PTX‑treated ovarian cancer cells. The expression and phosphorylation levels of ERK and AKT were markedly increased in response to PL‑PTX treatment. In addition, the inhibitory effects of PL‑PTX on ovarian cancer cells were eliminated by neutralizing antibodies against TNF. The observations of the present study revealed that PL‑PTX induced ovarian cell apoptosis via the TNF‑dependent pathway, which was significantly inhibited with the employment of antibodies against TNF. In vivo analysis demonstrated that PL‑PTX treatment significantly inhibited ovarian tumor growth and prolonged the survival of tumor bearing mice. In conclusion, the findings of the present study have provided an insight into the potential mechanism of PL‑PTX‑induced apoptosis of ovarian cancer cells. As PL‑PTX has been reported to induce ovarian tumor cell apoptosis via the TNF‑induced ERK/AKT signaling pathway, PL‑PTX may serve as an efficient anticancer drug for the treatment of ovarian cancer.

View Figures

View References

1	Tempfer CB, El Fizazi N, Ergonenc H and Solass W: Metastasis of ovarian cancer to the breast: A report of two cases and a review of the literature. Oncol Lett. 11:4008–4012. 2016. View Article : Google Scholar : PubMed/NCBI
2	Shakeel S, Elit L, Akhtar-Danesh N, Schneider L and Finley C: Care delivery patterns, processes, and outcomes for primary ovarian cancer surgery: A Population-based review using a national administrative database. J Obstet Gynaecol Can. 39:25–33. 2017. View Article : Google Scholar : PubMed/NCBI
3	Yamamoto A, Miyasaka Y, Furuya K, Watanabe H, Maruyama M, Nakada H, Takano A, Hada M, Nakagomi H, Omata M and Oyama T: Pseudo-Meigs' syndrome due to ovarian metastases from colon cancer: A case report and review of the literature. Surg Case Rep. 2:1122016. View Article : Google Scholar : PubMed/NCBI
4	Pimentel C, Becquet M, Lavoue V, Henno S, Leveque J and Ouldamer L: Ovarian metastases from breast cancer: A series of 28 cases. Anticancer Res. 36:4195–4200. 2016.PubMed/NCBI
5	Lago V, Minig L and Fotopoulou C: Incidence of lymph node metastases in apparent Early-stage low-grade epithelial ovarian cancer: A comprehensive review. Int J Gynecol Cancer. 26:1407–1414. 2016. View Article : Google Scholar : PubMed/NCBI
6	Raave R, de Vries RB, Massuger LF, van Kuppevelt TH and Daamen WF: Drug delivery systems for ovarian cancer treatment: A systematic review and meta-analysis of animal studies. PeerJ. 3:e14892015. View Article : Google Scholar : PubMed/NCBI
7	Munhoz RR, Pereira AA, Sasse AD, Hoff PM, Traina TA, Hudis CA and Marques RJ: Gonadotropin-releasing hormone agonists for ovarian function preservation in premenopausal women undergoing chemotherapy for Early-stage breast cancer: A systematic review and Meta-analysis. JAMA Oncol. 2:65–73. 2016. View Article : Google Scholar : PubMed/NCBI
8	Bian C, Yao K, Li L, Yi T and Zhao X: Primary debulking surgery vs. neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer. Arch Gynecol Obstet. 293:163–168. 2016. View Article : Google Scholar : PubMed/NCBI
9	Ong BY, Ranganath SH, Lee LY, Lu F, Lee HS, Sahinidis NV and Wang CH: Paclitaxel delivery from PLGA foams for controlled release in post-surgical chemotherapy against glioblastoma multiforme. Biomaterials. 30:3189–3196. 2009. View Article : Google Scholar : PubMed/NCBI
10	Ansaloni L, Coccolini F, Morosi L, Ballerini A, Ceresoli M, Grosso G, Bertoli P, Busci LM, Lotti M, Cambria F, et al: Pharmacokinetics of concomitant cisplatin and paclitaxel administered by hyperthermic intraperitoneal chemotherapy to patients with peritoneal carcinomatosis from epithelial ovarian cancer. Br J Cancer. 112:306–312. 2015. View Article : Google Scholar : PubMed/NCBI
11	Karmakar S, Banik NL and Ray SK: Combination of all-trans retinoic acid and paclitaxel-induced differentiation and apoptosis in human glioblastoma U87MG xenografts in nude mice. Cancer. 112:596–607. 2008. View Article : Google Scholar : PubMed/NCBI
12	Nikanjam M, Gibbs AR, Hunt CA, Budinger TF and Forte TM: Synthetic nano-LDL with paclitaxel oleate as a targeted drug delivery vehicle for glioblastoma multiforme. J Control Release. 124:163–171. 2007. View Article : Google Scholar : PubMed/NCBI
13	Merighi S, Benini A, Mirandola P, Gessi S, Varani K, Leung E, Maclennan S, Baraldi PG and Borea PA: Hypoxia inhibits paclitaxel-induced apoptosis through adenosine-mediated phosphorylation of bad in glioblastoma cells. Mol Pharmacol. 72:162–172. 2007. View Article : Google Scholar : PubMed/NCBI
14	Slaughter KN, Moore KN and Mannel RS: Anti-angiogenic therapy versus dose-dense paclitaxel therapy for frontline treatment of epithelial ovarian cancer: Review of phase III randomized clinical trials. Curr Oncol Rep. 16:4122014. View Article : Google Scholar : PubMed/NCBI
15	Lv W, Cheng L and Li B: Development and evaluation of a novel TPGS-mediated paclitaxel-loaded PLGA-mPEG nanoparticle for the treatment of ovarian cancer. Chem Pharm Bull (Tokyo). 63:68–74. 2015. View Article : Google Scholar : PubMed/NCBI
16	Lai J, Cai Q, Biel MA, Wang C, Hu X, Wang S and Lin J: Id1 and NF-kB promote the generation of CD133+ and BMI-1+ keratinocytes and the growth of xenograft tumors in mice. Int J Oncol. 44:1481–1489. 2014. View Article : Google Scholar : PubMed/NCBI
17	Griffith TS, Anderson RD, Davidson BL, Williams RD and Ratliff TL: Adenoviral-mediated transfer of the TNF-related apoptosis-inducing ligand/Apo-2 ligand gene induces tumor cell apoptosis. J Immunol. 165:2886–2894. 2000. View Article : Google Scholar : PubMed/NCBI
18	Sato T, Yamauchi N, Sasaki H, Takahashi M, Okamoto T, Sakamaki S, Watanabe N and Niitsu Y: An apoptosis-inducing gene therapy for pancreatic cancer with a combination of 55-kDa tumor necrosis factor (TNF) receptor gene transfection and mutein TNF administration. Cancer Res. 58:1677–1683. 1998.PubMed/NCBI
19	Yang XJ, Zheng FY, Xu YS and Ou RY: Ovarian cancer initially presenting with isolated ipsilateral superficial inguinal lymph node metastasis: A case study and review of the literature. J Ovarian Res. 7:202014. View Article : Google Scholar : PubMed/NCBI
20	Debniak T, Gromowski T, Scott RJ, Gronwald J, Huzarski T, Byrski T, Kurzawski G, Dymerska D, Górski B, Paszkowska-Szczur K, et al: Management of ovarian and endometrial cancers in women belonging to HNPCC carrier families: Review of the literature and results of cancer risk assessment in Polish HNPCC families. Hered Cancer Clin Pract. 13:32015. View Article : Google Scholar : PubMed/NCBI
21	Ebell MH, Culp M, Lastinger K and Dasigi T: A systematic review of the bimanual examination as a test for ovarian cancer. Am J Prev Med. 48:350–356. 2015. View Article : Google Scholar : PubMed/NCBI
22	Han X, Chen J, Jiang M, Zhang N, Na K, Luo C, Zhang R, Sun M, Lin G, Zhang R, et al: Paclitaxel-paclitaxel prodrug nanoassembly as a versatile nanoplatform for combinational cancer therapy. ACS Appl Mater Interfaces. 8:33506–33513. 2016. View Article : Google Scholar : PubMed/NCBI
23	Fukuchi M, Mochiki E, Ishiguro T, Ogura T, Sobajima J, Kumagai Y, Ishibashi K and Ishida H: Efficacy of Nab-paclitaxel as Second-line chemotherapy for unresectable or recurrent gastric cancer. Anticancer Res. 36:6699–6703. 2016. View Article : Google Scholar : PubMed/NCBI
24	Zhang T, Luo J, Fu Y, Li H, Ding R, Gong T and Zhang Z: Novel oral administrated paclitaxel micelles with enhanced bioavailability and antitumor efficacy for resistant breast cancer. Colloids Surf B Biointerfaces. 150:89–97. 2017. View Article : Google Scholar : PubMed/NCBI
25	Edwards SJ, Barton S, Thurgar E and Trevor N: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: A systematic review and economic evaluation. Health Technol Assess. 19:1–480. 2015. View Article : Google Scholar
26	Narod SA: Weekly vs. every-3-week paclitaxel for ovarian cancer. N Engl J Med. 374:26022016. View Article : Google Scholar : PubMed/NCBI
27	Dessai SB, Chakraborty S, Babu TV, Nayanar S, Bhattacharjee A, Jones J, Balasubramanian S and Patil VM: Tolerance of weekly metronomic paclitaxel and carboplatin as neoadjuvant chemotherapy in advanced ovarian cancer patients who are unlikely to tolerate 3 weekly paclitaxel and carboplatin. South Asian J Cancer. 5:63–66. 2016. View Article : Google Scholar : PubMed/NCBI
28	Perkins CL, Fang G, Kim CN and Bhalla KN: The role of Apaf-1, caspase-9, and bid proteins in etoposide- or paclitaxel-induced mitochondrial events during apoptosis. Cancer Res. 60:1645–1653. 2000.PubMed/NCBI
29	Pan J, Xu G and Yeung SC: Cytochrome c release is upstream to activation of caspase-9, caspase-8, and caspase-3 in the enhanced apoptosis of anaplastic thyroid cancer cells induced by manumycin and paclitaxel. J Clin Endocrinol Metab. 86:4731–4740. 2001. View Article : Google Scholar : PubMed/NCBI
30	Oktem M, Dilek TU, Guner H and Tiras MB: The effect of recombinant GM-CSF on IL-6 and TNF-alpha levels in epithelial ovarian cancer patients who received paclitaxel and cisplatinum: Preliminary results. Eur J Gynaecol Oncol. 25:478–480. 2004.PubMed/NCBI
31	Suyama H, Igishi T, Sano H, Matsumoto S, Shigeoka Y, Nakanishi H, Endo M, Burioka N, Hitsuda Y and Shimizu E: ERK activation and subsequent RB phosphorylation are important determinants of the sensitivity to paclitaxel in lung adenocarcinoma cells. Int J Oncol. 24:1499–1504. 2004.PubMed/NCBI
32	Atjanasuppat K, Lirdprapamongkol K, Jantaree P and Svasti J: Non-adherent culture induces paclitaxel resistance in H460 lung cancer cells via ERK-mediated up-regulation of βIVa-tubulin. Biochem Biophys Res Commun. 466:493–498. 2015. View Article : Google Scholar : PubMed/NCBI
33	Wu G, Qin XQ, Guo JJ, Li TY and Chen JH: AKT/ERK activation is associated with gastric cancer cell resistance to paclitaxel. Int J Clin Exp Pathol. 7:1449–1458. 2014.PubMed/NCBI
34	Cheng YJ, Lee CH, Lin YP, Huang JY, Su CC, Chang WT and Yang BC: Caspase-3 enhances lung metastasis and cell migration in a protease-independent mechanism through the ERK pathway. Int J Cancer. 123:1278–1285. 2008. View Article : Google Scholar : PubMed/NCBI